Children’s Oncology Group guidelines standardize pediatric radiotherapy simulation across treatment sites and techniques
COG guidelines standardize pediatric radiotherapy simulation across treatment sites and techniques
Tag
high relevance
Concurrent olaparib increased severe dermatitis during radiotherapy for inflammatory breast cancer
Adding low-dose olaparib increased grade 3 dermatitis from 5.5% to 24.7% during postmastectomy radiotherapy for inflammatory breast cancer.
Short-course total neoadjuvant therapy improved five-year survival in STELLAR
Five-year overall survival was 78.1% with short-course total neoadjuvant therapy versus 69.7% with long-course chemoradiotherapy.
Three-week locoregional breast radiotherapy was noninferior for arm lymphedema
40 Gy in 15 fractions did not increase three-year arm lymphedema or compromise recurrence and mortality outcomes compared with 50 Gy.
Oxaliplatin-based total neoadjuvant therapy improved three-year DFS in high-risk rectal cancer
Doublet total neoadjuvant therapy improved three-year disease-free survival, metastasis-free survival, and pathological complete response compared with conventional chemoradiotherapy.
ESTRO defined minimum standards for prostate SBRT implementation
ESTRO recommends prostate SBRT for selected intermediate-risk disease with MRI-based contouring, rigorous quality assurance, and daily image guidance.
Immune-sparing lung SBRT planning reduced lymphocyte loss in a randomized phase II trial
Optimizing dose to blood- and immune-rich structures reduced lymphocyte depletion and prevented grade 3 lymphopenia after early-stage lung SBRT.
RadComp protons lowered mean cardiac dose without improving early cardiac-related quality of life
Protons substantially reduced mean cardiac exposure, but no cardiac dose metric predicted patient-reported symptoms during the first six months.
Most PLATO quality-of-life deficits recovered by six months, but advanced disease remained burdensome
Most treatment-related deficits improved by six months, although bowel and sexual problems persisted in several standard-dose and locally advanced groups.
Prolonged first-generation antiandrogens showed no survival benefit with prostate radiotherapy
Extending first-generation antiandrogen therapy beyond short-term use was not associated with better survival and may increase early ADT discontinuation.
Hydrogel spacers reduced invasive treatment for radiation proctitis after prostate radiotherapy
Hydrogel spacer placement was associated with a 74% lower risk of gastrointestinal endoscopic hemostasis after prostate radiotherapy.
ESTRO defines clinical standards for high-dose thoracic reirradiation in NSCLC
ESTRO recommends selective high-dose thoracic reirradiation with comprehensive staging, limited target volumes and formal cumulative dose assessment.
Durvalumab improved 2-year progression-free survival after chemoradiotherapy in real-world stage III NSCLC
Consolidation durvalumab after concurrent chemoradiotherapy halved the adjusted risk of progression or death at two years in real-world stage III NSCLC.
Postoperative radiotherapy provided better quality of life and value in oral cavity cancer
Postoperative conventional radiotherapy caused fewer head-and-neck symptoms and dominated preoperative accelerated radiotherapy in the five-year cost-utility analysis.
FDG-PET and multiparametric MRI did not reliably predict pCR in esophageal cancer
Combined FDG-PET and multiparametric MRI achieved only modest pCR prediction after neoadjuvant chemoradiotherapy, with a cross-validated AUC of 0.65.